New cancer drug combo tested in early trial

NCT ID NCT05904496

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This early-phase study tested a new drug called BGB-30813, alone or with another drug (tislelizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drugs could shrink tumors. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601-1915, United States

  • Hospital Universitario Vall Dhebron

    Barcelona, 08035, Spain

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Linear Clinical Research

    Nedlands, Western Australia, 6009, Australia

  • Md Anderson Cancer Center

    Houston, Texas, 77030-3907, United States

  • Monash Health

    Clayton, Victoria, 3168, Australia

  • Next Oncology

    San Antonio, Texas, 78229-6028, United States

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Shandong Cancer Hospital

    Jinan, Shandong, 250117, China

  • Shandong Provincial Hospital

    Jinan, Shandong, 250021, China

  • Start Madrid Fundacion Jimenez Diaz

    Madrid, 28040, Spain

Conditions

Explore the condition pages connected to this study.